Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To determine the accuracy of biplane transrectal ultrasonography (TRUS) plus ultrasonic elastosonography (UE) and contrast-enhanced ultrasonography (CEUS) in preoperative T staging after neoadjuvant chemoradiotherapy for rectal cancer.
Materials And Methods: Fifty-three patients with advanced lower rectal cancer were examined before and after neoadjuvant chemoradiotherapy with use of TRUS plus UE and CEUS and were diagnosed as having T stage disease. We compared ultrasonic T stages before and after neoadjuvant chemoradiotherapy and analyzed any changes. Also, with postoperative pathological stages as the gold standard, we compared ultrasonic and pathological T stages and determined their consistency by the kappa statistic.
Results: For patients with rectal cancer, ultrasonic T stages were lower after neoadjuvant chemoradiotherapy than before, with a statistically significant difference (P < 0.05). The posttreatment downstaging rate was 39.6% (21/53). A total of 84.9% received correct staging with use of biplane TRUS plus UE and CEUS in the evaluation of preoperative T staging after neoadjuvant chemoradiotherapy for rectal cancer, which was highly consistent with that of pathological staging (κ = 0.768, P < 0.05). Its sensitivities were 80.0%, 50.0%, 75.0%, 96.3%, and 100% in the diagnoses of stages T0 to T4 rectal cancers, respectively; the specificities were 95.4%, 97.9%, 95.1%, 88.5%, and 100% at stages T0 to T4, respectively.
Conclusion: Biplane TRUS plus UE and CEUS can be used to accurately perform preoperative T staging in rectal cancer after neoadjuvant chemoradiotherapy; in addition, this procedure well reflects changes in depth of rectal cancer invasion into the intestinal wall before and after neoadjuvant chemoradiotherapy. It is of great value in clinically evaluating the efficacy of neoadjuvant chemoradiotherapy, in selecting therapeutic regimens, and in avoiding overtreatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejrad.2018.04.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation Therapy for Solitary Fibrous Tumor of the Orbit.
Ophthalmic Plast Reconstr Surg
September 2025
Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center.
Solitary fibrous tumor, formerly also referred to as hemangiopericytoma, is a fibroblastic mesenchymal neoplasm of the orbit that rarely metastasizes but has a propensity for local recurrence. We describe 5 cases of orbital solitary fibrous tumors that were treated with radiation. In 3 patients, radiation therapy was given in the neoadjuvant setting prior to surgery.
View Article and Find Full Text PDFEfficacy of Topical Chemotherapy in Ocular Adnexal Sebaceous Carcinoma.
Ophthalmic Plast Reconstr Surg
September 2025
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
This study aimed to report clinical outcomes of topical chemotherapy for ocular adnexal sebaceous carcinoma (OaSC) with intraepithelial spread. A retrospective chart review of patients with OaSC treated at the Bascom Palmer Eye Institute between 2000 and 2023 was conducted. Patient inclusion criteria included: (1) biopsy-proven diagnosis of OaSC, (2) intraepithelial pagetoid involvement confirmed by conjunctival map biopsy, (3) implementation of topical chemotherapy for tumor control, and (4) repeat conjunctival map biopsy following cessation of topical chemotherapy.
View Article and Find Full Text PDFRhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome.
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFPyrotinib versus Pertuzumab with Trastuzumab and Taxane in HER2-Positive Metastatic Breast Cancer: A Chinese Multicenter Real-world Study.
Oncologist
September 2025
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Background: THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce. This study evaluates and compares the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.
View Article and Find Full Text PDFReal-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.